NASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis $3.40 +0.15 (+4.45%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Savara Stock (NASDAQ:SVRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Savara alerts:Sign Up Key Stats Today's Range$3.28▼$3.4350-Day Range$2.32▼$3.2752-Week Range$2.26▼$5.31Volume262,158 shsAverage Volume1.30 million shsMarket Capitalization$587.82 millionP/E RatioN/ADividend YieldN/APrice Target$8.83Consensus RatingModerate Buy Company OverviewSavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More… Savara Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreSVRA MarketRank™: Savara scored higher than 35% of companies evaluated by MarketBeat, and ranked 790th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingSavara has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSavara has only been the subject of 1 research reports in the past 90 days.Read more about Savara's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.45) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -7.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -7.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Savara's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.95% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.Change versus previous monthShort interest in Savara has recently increased by 2.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.95% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.Change versus previous monthShort interest in Savara has recently increased by 2.80%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.86 News SentimentSavara has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Savara this week, compared to 3 articles on an average week.Search Interest4 people have searched for SVRA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.13% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Savara's insider trading history. Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address SVRA Stock News HeadlinesSavara Announces Participation in the Upcoming Citizens Life Sciences ConferenceMay 1 at 4:17 PM | businesswire.comSavara: Make-It-Or-Break-It Molbreevi BLA FilingApril 21, 2025 | seekingalpha.comTrump Makes Major Crypto AnnouncementTrump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick. May 2, 2025 | Crypto 101 Media (Ad)Savara Inc. Announces Equity Awards for New EmployeesApril 16, 2025 | msn.comSavara Announces New Employment Inducement GrantApril 11, 2025 | businesswire.comSavara announces encore presentations from Molgramostim Phase 3 IMPALA-2 trialApril 8, 2025 | markets.businessinsider.comSavara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific ConferencesApril 7, 2025 | businesswire.comTuesday 4/1 Insider Buying Report: NTAP, SVRAApril 4, 2025 | nasdaq.comSee More Headlines SVRA Stock Analysis - Frequently Asked Questions How have SVRA shares performed this year? Savara's stock was trading at $3.07 at the beginning of 2025. Since then, SVRA stock has increased by 10.3% and is now trading at $3.3850. View the best growth stocks for 2025 here. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) released its quarterly earnings data on Thursday, March, 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.02. The business earned $0.27 million during the quarter. Who are Savara's major shareholders? Savara's top institutional investors include Emerald Advisers LLC (1.79%), Emerald Mutual Fund Advisers Trust (1.17%), Bank of New York Mellon Corp (0.15%) and Rhumbline Advisers (0.09%). Insiders that own company stock include Rick Yang, David A Ramsay, Matthew Pauls, David L Lowrance, Joseph S Mccracken, Raymond Dennis Pratt and Nevan C Elam. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some other companies that Savara investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Southern First Bancshares (SFST) and TotalEnergies (TTE). Company Calendar Last Earnings3/27/2025Today5/02/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$8.83 High Stock Price Target$15.00 Low Stock Price Target$5.00 Potential Upside/Downside+161.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.89% Return on Assets-46.44% Debt Debt-to-Equity Ratio0.13 Current Ratio17.70 Quick Ratio17.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book3.25Miscellaneous Outstanding Shares172,633,000Free Float162,815,000Market Cap$584.36 million OptionableOptionable Beta0.52 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SVRA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.